Susquehanna International Group, LLP Bellus Health Inc. Call Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 16, 2023	SELL	$7.14 - $8.53 $158,508 - $189,366	-22,200 Reduced 67.07%	10,900 $78,000
Q4 2022 Feb 14, 2023	SELL	$8.22 - $10.76 $278,658 - $364,764	-33,900 Reduced 50.6%	33,100 $272,000
Q3 2022 Nov 14, 2022	BUY	$8.95 - $12.0 $299,825 - $402,000	33,500 Added 100.0%	67,000 $708,000
Q2 2022 Aug 15, 2022	BUY	$6.46 - $10.02 $142,766 - $221,442	22,100 Added 193.86%	33,500 $310,000
Q1 2022 May 16, 2022	SELL	$5.56 - $7.99 $179,032 - $257,278	-32,200 Reduced 73.85%	11,400 $78,000
Q4 2021 Feb 14, 2022	SELL	$5.26 - $8.3 $841,074 - $1.33 Million	-159,900 Reduced 78.57%	43,600 $351,000
Q3 2021 Nov 15, 2021	BUY	$2.7 - $6.64 $549,450 - $1.35 Million	203,500 New	203,500 $1.25 Million

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.